dc.contributor.author
Bellido, Virginia
dc.contributor.author
Pérez Pérez, Antonio
dc.contributor.author
Universitat Autònoma de Barcelona
dc.identifier
https://ddd.uab.cat/record/238674
dc.identifier
urn:10.1007/s13300-020-00966-z
dc.identifier
urn:oai:ddd.uab.cat:238674
dc.identifier
urn:articleid:18696961p1
dc.identifier
urn:pmcid:PMC7718834
dc.identifier
urn:pmc-uid:7718834
dc.identifier
urn:pmid:33278017
dc.identifier
urn:oai:pubmedcentral.nih.gov:7718834
dc.description.abstract
Diabetes is one of the most common comorbidities in hospitalized patients with coronavirus disease 2019 (COVID-19). Inpatient hyperglycemia during this pandemic has been associated with worse outcomes, so it is mandatory to implement effective glycemic control treatment approaches for inpatients with COVID-19. The shortage of personal protective equipment, the need to prevent staff exposure, or the fact that many of the healthcare professionals might be relatively unfamiliar with the management of hyperglycemia may lead to worse glycemic control and, consequently, a worse prognosis. In order to reduce these barriers, we intend to adapt established recommendations to manage hyperglycemia during this pandemic in critical and noncritical care settings.
dc.format
application/pdf
dc.relation
Diabetes Therapy ; december 2020, p. 1-12
dc.rights
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
dc.rights
https://creativecommons.org/licenses/by-nc/4.0/
dc.subject
Insulin therapy
dc.title
Inpatient Hyperglycemia Management and COVID-19
dc.type
Article de revisió